1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
1 citations
,
May 2025 in “Clinical Reviews in Allergy & Immunology” January 2022 in “Drugs of Today”
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Microneedling may improve melasma treatment by boosting topical therapy effectiveness.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
1 citations
,
October 2013 in “The American Journal of Gastroenterology” Infliximab can trigger lupus-like symptoms in Crohn's disease patients.
2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
4 citations
,
September 2020 in “Cell division” XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
November 2025 in “JEADV Clinical Practice” Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
20 citations
,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
1 citations
,
October 2025 in “Nano Research” A new microneedle patch effectively treats atopic dermatitis by reducing skin stress and restoring immune balance.
1 citations
,
October 2019 in “Journal of Thoracic Oncology” Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
6 citations
,
November 2017 in “Journal of the European Academy of Dermatology and Venereology” A woman got melanoma on her scalp after anti-hair loss treatment with injections.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
5 citations
,
July 2024 in “Pediatric Dermatology” Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
July 2024 in “Journal of Investigative Dermatology”
14 citations
,
January 2016 in “Experimental and molecular pathology” Giving immune serum from vaccinated mice to mice without T cells prevents infection and tumor growth.
26 citations
,
July 2007 in “Biochemical Pharmacology” ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.
May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
A new peptide, murikal/SPR4, was found to significantly increase hair growth in mice, and its liposomal topical formulations enhanced hair growth more than commercial products. However, results on human scalp skin were unclear, needing more tests.
5 citations
,
November 2024 in “Journal of Clinical Immunology” Dupilumab effectively controls symptoms in infants with Netherton syndrome.
51 citations
,
August 2015 in “Cochrane library” Methotrexate is not proven to maintain remission in ulcerative colitis.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
March 2016 in “Reactions Weekly” A woman experienced hair loss, nail changes, bone marrow suppression, and low blood protein after taking azathioprine.
1 citations
,
September 2024 in “Dermatological Reviews” Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.